%0 Conference Paper
%A Kinton, Sofia
%A Dujardin, Simon
%A Levit, Mikhail
%A Pao, Ping-Chieh
%A Sardi, Pablo
%A Zhang, Bailin
%A Dodge, James
%A Krishnan, Rajaraman
%A Rizzo, Marianna
%A Teunissen, Charlotte E
%A Zetterberg, Henrik
%A Blennow, Kaj
%A Kollmorgen, Gwendlyn
%A Ramia, Nancy
%A Fernandes, Sara B Gomes
%A Krüger, Rejko
%A Borejko, Olga
%A Aarsland, Dag
%A Hu, Michele
%A Klockgether, Thomas
%A Brockmann, Kathrin
%A Gasser, Thomas
%A Jessen, Frank
%A Spottke, Annika
%A van der Flier, Wiesje M
%A Lemstra, Afina W
%A Tijms, Betty M
%A Frisoni, Giovanni B
%A Hort, Jakub
%A Nedelska, Zuzana
%A Chevalier, Claire
%A Visser, Pieter Jelle
%A Vos, Stephanie J B
%T Proteomic Profiling of CSF Reveals Inflammatory Pathways Associated with Tau Neuropathology in Alzheimer's Disease
%J Alzheimer's and dementia
%V 21
%N S2
%@ 1552-5260
%M DZNE-2026-00051
%P e106780
%D 2025
%X Aggregation of amyloid beta (Aβ) and tau proteins is a hallmark of Alzheimer's disease (AD) and tauopathies. In AD, extracellular deposition of Aβ peptide precedes tau aggregation and the onset of neuroinflammatory processes. Both neuroinflammation and tau deposition are associated with synaptic loss, neurodegeneration, and cognitive decline. However, the precise sequence of events from amyloid deposition to tau aggregation, neuroinflammation, and neurodegeneration remains unclear. A cross-sectional analysis of tau and other proteins in the cerebrospinal fluid (CSF) of AD patients can provide insight into the inflammatory and degenerative processes. Tau levels may be used as a proxy for disease progression, and we hypothesize that the expression of neuroinflammatory markers will be modulated in response to increasing tau aggregation.To investigate this, we collaborated with the EPND-biomarker consortium to analyze over 150 human CSF samples from AD and control patients. We measured levels of Aβ1-40, Aβ1-42, pTau181, and total tau, and conducted proteomic profiling using the O-link and SomaScan platforms. Next, AD patients were stratified into Aβ+Tau+ and Aβ+Tau- groups to identify biomarkers associated with Aβ and/or tau aggregation.As expected, inflammation markers were elevated in AD CSF samples compared to controls. Interestingly, we observed distinct correlations between these markers and amyloid versus tau pathology biomarkers. Approximately 10
%B Alzheimer’s Association International Conference
%C 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2 27 Jul 2025 - 31 Jul 2025
M2 Toronto, Canada
%K Humans
%K Biomarkers: cerebrospinal fluid
%K Alzheimer Disease: cerebrospinal fluid
%K tau Proteins: cerebrospinal fluid
%K Amyloid beta-Peptides: cerebrospinal fluid
%K Female
%K Male
%K Aged
%K Cross-Sectional Studies
%K Proteomics
%K Middle Aged
%K Peptide Fragments: cerebrospinal fluid
%K Biomarkers (NLM Chemicals)
%K tau Proteins (NLM Chemicals)
%K Amyloid beta-Peptides (NLM Chemicals)
%K Peptide Fragments (NLM Chemicals)
%F PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
%9 AbstractJournal Article
%$ pmid:41505027
%R 10.1002/alz70856_106780
%U https://pub.dzne.de/record/283155